EVO756
Chronic Spontaneous Urticaria
Key Facts
About Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profile